Page 4 - Eva Kalias News Today

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they

Pratteln, Switzerland, October 3, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the Company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA)

Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in...

Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in JAMA Neurology (https://jamanetwork.com/journals/jamaneurology/fullarticle/2795868?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamaneurol.2022.2480)Safety

Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot

Pratteln, Switzerland, June 30, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Annual General Meeting (AGM) held

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Updates on Ongoing NDA Submission for Vamorolone

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 27, 2022 -- Santhera Pharmaceuticals (SIX: SANN) announces that Chairman of the Board Elmar Schnee will not stand for re-election